Abbott opposes the NGAL trauma patent at EPO.

By On 24. September 2012 · Leave a Comment · In BioPorto

As expected the trauma patent at EPO didn’t stay unopposed.

First in line (as expected) we find (presumably) Abbott, represented by Harvey Vaughan John Adams.

As with the opposition of the NGAL cut-off patent, they request the revocation of the entire patent.

Well, it was a hardly a surprise. Lets see who joins the oppostion, and (more important) who doesn’t.

http://medicoinvestor.com/wp-content/uploads/2012/09/Opposition-against-the-Trauma-Patent.pdf

 

About Karl M. Bidstrup

Tidligere ejer af Medicoinvestor.com Strategien har gennem mange år været at profitere på etablerede aktier, og brænde det hele af på Bioporto... Sad but true. Kontakt mig på medicoinvestor(A)gmail.com hvis du har en million du ikke ved hvor du skal gemme, så skal jeg nok holde den for dig. 🙂

Related posts:

  1. The recent development in Triage/Trauma NGAL-patent The USPTO’s Christine Foster ist still not happy with the...
  2. BioPorto, status of Trauma Patent at USPTO I said to myself  “I wonder what the present status...
  3. BioPorto, status of Trauma Patent at USPTO (II) Last week I gave myself a fright, when browsing the...
  4. NEW PATENT: Methods For Rapid Assessment of Severity of a Trauma On the 28’th of December 2011, EPO issued the patent...
  5. Revokation of CCH’s NGAL patent (Cincinnati Children’s Hospital) We have the greatest respect for the work of CCH,...
 

Leave a Reply

Your email address will not be published. Required fields are marked *

Set your Twitter account name in your settings to use the TwitterBar Section.